Telix announced completion of patient enrollment in the Phase 1 IPAX-2 trial of TLX101-Tx for newly diagnosed glioblastoma, with no dose-limiting toxicities observed including at the maximum dose. This de-risks the safety profile of TLX101-Tx as it advances alongside the pivotal Phase 3 IPAX BrIGHT trial in recurrent GBM, but the readout is early-stage safety data with no efficacy results.
TLX drugs
TLX drug pipeline →- ◆ ITM-11 4/10 Phase 3 (completed)
- ● TLX591-Tx 4/10 Phase 3
- ● Zircaix 4/10 Phase 3 (ZIRCON) completed; BLA under FDA review
- ▲ Gozellix 3/10 Approved (FDA, March 21, 2025 — NDA 219592, 505(b)(2))
- ● TLX101-Tx 3/10 Phase 3 (pivotal, just initiated); Phase 1 safety stage complete
- All TLX drugs, catalysts & trials →
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 19 $10.17entry
- T+1 · 6mo ago +1.08%α +0.04% · $10.28
- T+5 · 6mo ago −4.23%α −6.52% · $9.74
- T+20 · 5mo ago −2.26%α −3.25% · $9.94
- T+60 · 3mo ago +21.24%α +14.95% · $12.33
Price Chart
How similar events traded
Executive Summary
Telix announced completion of patient enrollment in the Phase 1 IPAX-2 trial of TLX101-Tx for newly diagnosed glioblastoma, with no dose-limiting toxicities observed including at the maximum dose. This de-risks the safety profile of TLX101-Tx as it advances alongside the pivotal Phase 3 IPAX BrIGHT trial in recurrent GBM, but the readout is early-stage safety data with no efficacy results.
Key Facts
- IPAX-2 Phase 1 study (TLX101-Tx in newly diagnosed GBM) completed enrollment of 12 patients across 3 cohorts.
- No dose-limiting toxicities (DLTs) observed, including at the maximum administered dose of 10 GBq (two 5 GBq doses).
- ,
- ],
Financial Impact
Not specified
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3297047 |
Track record
27 reports on TLX
9 of 20 bullish or bearish reports moved the stock their way by T+1. Best: +29.26% at T+20 after the Jun 1, 2026 report. 18 of 20 went positive at some point.
Filters
- Oct 29, 202618d ago 6-K Neutral 5/10 Entry $9.10 to $9.05 Now $8.92 −1.98% ▼ −0.55% −0.07% vs SPY
- Oct 20, 202627d ago 6-K Neutral 4/10 No price data
- Oct 20, 202627d ago Press Release Bullish 6/10 Entry $10.03 to $9.54 Now $8.92 −11.07% ▼ −4.89% −3.70% vs SPY
- Sep 29, 20266w ago 6-K Bullish 6/10 Entry $10.97 to $10.72 Now $8.92 −18.69% ▼ −2.28% −2.46% vs SPY
- Sep 21, 20268w ago 6-K Bullish 7/10 Entry $11.31 to $11.95 Now $8.92 −21.13% ▲ +5.66% +5.67% vs SPY
- Sep 20, 20268w ago Press Release Bullish 7/10 Entry $11.31 to $11.95 Now $8.92 −21.13% ▲ +5.66% +5.67% vs SPY
- Sep 14, 20269w ago 6-K Bullish 8/10 Entry $12.83 to $11.83 Now $8.92 −30.48% ▼ −7.79% −7.35% vs SPY
- Sep 14, 20269w ago Press Release Bullish 8/10 Entry $11.78 to $12.83 Now $8.92 −24.28% ▲ +8.91% +9.37% vs SPY
- Sep 1, 202610w ago 6-K Bullish 7/10 Entry $11.45 to $11.74 Now $8.92 −22.10% ▲ +2.53% +1.49% vs SPY
- Sep 1, 202610w ago Press Release Bullish 6/10 Entry $11.45 to $11.74 Now $8.92 −22.10% ▲ +2.53% +1.49% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers